Peptides:

The peptide portion was built up at the PAM resin. The amino acids were protected with N-Boc. The protecting groups of the side chains were: Cys(Acm), Lys(2-Cl-Z), Thr(Bzl) D-Trp(For). The resin was swelled overnight in DCM and washed with DMF. A reaction cycle consisted of: a) cleavage of the N-terminal Boc group by a short wash step, followed by shaking the resin with TFA/p-cresol (95.5, v/v) for 1 min., b) pre-activation of a solution of 4 eq. of the Boc-protected monomer for 2 min. in DMSO with 3.9 eq. HATU and 10 eq. DIEA, c) washing the resin with DMF (1 min. vacuum-supported flow), d) coupling of the pre-activated amino acid for 3 min., e) washing of the resin with DMF (1 min. vacuum-supported flow). After each coupling step, a sample was taken to determine the acylation efficiency. It was determined by means of the quantitative ninhydrin reaction (Sarin et al., Anal. Biochem. 117, pages 147-157 (1981)). A sample was separated from the resin, deprotected and analyzed by means of HPLC. This analysis resulted in the fact that the H-D-Phe-Cys(Acm)-Phe-D-Trp-Lys-Thr-Cys(Acm)-Thr-OH (SEQ ID NO:5) had formed in a yield of > 95%. The resin-bound peptide was cyclized with two times the excess of T1$(FFA)_3$ in DMF at room temperature. Analysis of deprotected samples separated from the resin led to the result that the formation of H-D-Phe-cyclo[Cys-Phe-D-Trp-Lys-Thr-Cys]-Thr-OH (SEQ ID NO:5) was substantially concluded within one hour.

IN THE CLAIMS:

Please amend the claims as follows:

4. (Amended) The oligonucleotide conjugate according to claim 1, wherein the 3' end in the oligonucleotide is covalently bonded to a propanediol group.

5. (Amended) The oligonucleotide conjugate according to claim 1, wherein the somatostatin analog is octreotide or octreotate, or a derivative thereof.

A7

6. (Amended) The oligonucleotide conjugate according to claim 1, wherein the somatostatin analog is covalently bonded to the 5' end of the oligonucleotide molecule.

7. (Amended) The oligonucleotide conjugate according to claim 1, wherein the somatostatin analog is covalently bonded to a base present in the oligonucleotide molecule via a spacer.

A8

9. (Amended) The oligonucleotide conjugate according to claim 1, wherein the intracellular nucleic acid sequence is an mRNA or viral RNA.

A9

11. (Amended) The oligonucleotide conjugate according to claim 1, wherein the oligonucleotide has a length of 8 to 50 nucleotides.